Autor: |
de Groote, Pascal, Helbecque, Nicole, Lamblin, Nicolas, Hermant, Xavier, Mc Fadden, Eugène, Foucher-Hossein, Claude, Amouyel, Philippe, Dallongeville, Jean, Bauters, Christophe |
Zdroj: |
Pharmacogenetics and Genomics; March 2005, Vol. 15 Issue: 3 p137-142, 6p |
Abstrakt: |
Previous studies have clearly demonstrated the beneficial effect of -blockers in patients with stable congestive heart failure (CHF). -blockers improve left ventricular ejection fraction (LVEF) and reduce cardiac mortality. However, there is an interindividual variability in the response to these agents. Two studies have suggested a possible impact of some functional AR gene polymorphisms on the effects of -blockade. The objective of the study is to analyse the association between genetic variations in the 1or the 2adrenoreceptor (AR) gene and the effects of -blockade in patients with stable CHF. We studied 199 consecutive patients with stable CHF not treated with -blockers. Before introduction of -blockers and 3 months after the maximal tolerated dose was reached, patients underwent an echocardiography and a radionuclide angiography. The 1ARGly389Arg, 1ARSer49Gly, 2ARGly16Arg, 2ARGln27Glu and 2ARThr164Ile polymorphisms were determined -blockade resulted in a significant decrease in heart rate, a significant increase in LVEF (from 30±10 to 40±13, P<0.0001). There was no association between the five polymorphisms and heart rate or LVEF, either before or after -blockade. Heart rate and LVEF responses to -blockade were not associated with the 1AR or the 2AR polymorphisms. AR polymorphisms did not explain the interindividual variability in the response to -blockers. |
Databáze: |
Supplemental Index |
Externí odkaz: |
|